Gastrointestinal SymptomsNCT07742657
A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels
A study testing Super Liver in people with Gastrointestinal Symptoms and Bloating, run by SuperBonsai Inc. at 1 site in United States.
Trial summary
This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. Read more about this study
- Who is it for?
- Ages 30 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Gastrointestinal Symptoms, Bloating, Digestive Discomfort
- What is being tested?
- Super Liver
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Jun 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female.
- Be aged 30-65 years (inclusive) at the time of enrollment.
- Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Willing and able to follow the study protocol as described.
- Willing to maintain their current diet, exercise routine, and sleep patterns, for the duration of the trial.
Show all 9Show fewer
- If taking other over-the-counter supplements or herbal remedies is willing to maintain this routine without introducing any other new products for the study duration.
- Resides in the United States.
- Willing to follow the study protocol as described.
Who cannot join
- Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine).
- Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
- Known history of gallbladder disease or bile duct obstruction.
- Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders.
- Has a planned surgery in the next 12 weeks.
- Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
Show all 9Show fewer
- Known history of substance abuse.
- Currently, or was in the past 3 months, a smoker.
- Currently participating in or planning to participate in another research study during the study period.
Trial locations and contacts
1 site in 1 country.
About this study
This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period.
Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.
- Conditions
- Gastrointestinal Symptoms, Bloating, Digestive Discomfort, Low Energy Levels, Brain Fog, Mood Instability
- Being tested
- Super Liver
- Medical subject headings
- Mental Fatigue, Sleep Initiation and Maintenance Disorders, Halitosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Super LiverDietary supplement
All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.
| Study group | Role | What they receive |
|---|---|---|
| Super Liver Arm | Experimental | Not described Receives: Dietary Supplement: Super Liver |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Gastrointestinal Symptom Rating Scale (GSRS)
Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.
Measured: Baseline to Week 12
Secondary outcomes (6)
Change in Self-Reported Energy Level Score
Change from baseline to Week 12 in participant-reported energy level, as assessed using the study questionnaire.
Measured: Baseline to Week 12
Change in Self-Reported Brain Fog Score
Change from baseline to Week 12 in participant-reported brain fog, as assessed using the study questionnaire.
Measured: Baseline to Week 12
Change in Self-Reported Mood Stability Score
Change from baseline to Week 12 in participant-reported mood stability, as assessed using the study questionnaire.
Measured: Baseline to Week 12
Change in Self-Reported Sleep Quality Score
Change from baseline to Week 12 in participant-reported sleep quality, as assessed using the study questionnaire.
Measured: Baseline to Week 12
Change in Self-Reported Skin Clarity Score
Change from baseline to Week 12 in participant-reported skin clarity, as assessed using the study questionnaire.
Measured: Baseline to Week 12
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Incidence, severity, and relationship to study product of treatment-emergent adverse events occurring from the first dose of study product through the end of the 12-week study period.
Measured: Continuous monitoring over 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start24 Jun 2026
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastrointestinal SymptomsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- SuperBonsai Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07742657
- Sponsor's protocol ID
- SUPER-30544
- Status last verified
- Jul 2026
- First submitted
- 6 Jul 2026
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels
- ClinicalTrials.gov ID
- NCT07742657
- Acronym / sponsor ID
- SUPER-30544
- Conditions
- Gastrointestinal Symptoms, Bloating, Digestive Discomfort, Low Energy Levels, Brain Fog, Mood Instability
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 35 participants (actual)
- Lead sponsor
- SuperBonsai Inc.Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 24 Jun 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period.
Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Super Liver Arm | Experimental | Dietary Supplement: Super Liver |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Be male or female.
- Be aged 30-65 years (inclusive) at the time of enrollment.
- Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Willing and able to follow the study protocol as described.
Key exclusion criteria (9 listed)
- Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine).
- Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
- Known history of gallbladder disease or bile duct obstruction.
- Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders.
- Has a planned surgery in the next 12 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Super LiverAll 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks. | Dietary supplement | Super Liver Arm |
Primary outcome
Change in Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Baseline to Week 12
Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.
6 secondary outcomes
Change in Self-Reported Energy Level Score
Time frame: Baseline to Week 12
Change in Self-Reported Brain Fog Score
Time frame: Baseline to Week 12
Change in Self-Reported Mood Stability Score
Time frame: Baseline to Week 12
Change in Self-Reported Sleep Quality Score
Time frame: Baseline to Week 12
Change in Self-Reported Skin Clarity Score
Time frame: Baseline to Week 12
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Continuous monitoring over 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
Related trials for Gastrointestinal Symptoms
Recruiting
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals
Gastrointestinal Microbiome (Focus), Gastrointestinal Symptoms
RecruitingObservational study
Impact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet
Celiac Disease, Gluten-free Diet
Not yet recruitingPhase 1/2
A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults
Digestive Symptoms, Gastrointestinal Symptoms
Recruiting
Trial Evaluating Nutritional Fiber in Digestive Symptoms of Endometriosis
Endometriosis, Microbiome Dysbiosis
Recruiting
IgG Binding Protein LT in Support of a Healthy Gut on the Go
Gut Health, Gastrointestinal Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Super Liver in people with Gastrointestinal Symptoms and Bloating, run by SuperBonsai Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Gastrointestinal Symptom Rating Scale (GSRS) (time frame: Baseline to Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.